Close Menu

People in the News

Feb 22, 2019

Jeffrey Alter, John Bigalke, Samuel Nussbaum, Lynne Powell

Progenity has appointed Jeffrey Alter, John Bigalke, Samuel Nussbaum, and Lynne Powell to its board of directors.

Alter is president of Arcturus One Consulting. He previously served as CEO of UnitedHealthcare's commercial group. Prior to that, he was senior VP of strategic financial planning for Oxford Health Plans. Before Oxford, he served as VP of finance, underwriting, and operations at Vytra Health Plans.

Bigalke is CEO of Second Half Healthcare Advisors. He is also chairman of VaxCares' advisory board and a member of Advent (formerly Adventist) Health System's advisory board. In addition, he is a senior advisor to Concord Management Services. Bigalke previously served as US national industry leader and senior partner for global healthcare and life sciences at Deloitte. Bigalke also was the firm's national director of public policy.

Nussbaum is a professor of clinical medicine at the Washington University School of Medicine. He is also a strategic consultant for EBG Advisors and a senior advisor to Sandbox Industries and the Ontario Teachers' Pension Plan. He serves on several boards, including those of Motus GI, Coherus Biosciences, and PhyMed. Prior to this, Nussbaum served as executive VP of clinical health policy and chief medical officer at Anthem. Previously, he was executive VP of medical affairs and system integration at BJC Healthcare. 

Powell serves as senior VP and chief commercial officer at BioCryst Pharmaceuticals. Prior to this, she was senior VP of North America at CSL Behring. Powell also served as the firm's VP of global commercial development and head of business development and European marketing. Prior to CSL, she held positions at Glaxo Wellcome's commercial strategy and clinical research organizations.

Feb 19, 2019

Anthony Schmidt

Circulogene has named Anthony Schmidt as the firm's medical director. He will lead the lab's precision medicine initiatives and educate the medical community about the firm's technologies. Schmidt was most recently pathology chair and lab medical director for the Mississippi Baptist Healthcare System.

Feb 19, 2019

Michael McGarrity

MDxHealth has appointed Michael McGarrity as its CEO and member of the firm's board of directors. Prior to MDxHealth, McGarrity served as CEO of Sterilis Medical. Previously, he was CEO of Nanosphere before it was acquired by Luminex in 2016. Prior to Nanosphere, McGarrity served in leadership roles at Stryker.

Feb 19, 2019

Andy Watson, Anthony Scarpello

Empire Genomics has appointed Andy Watson as CEO and Anthony Scarpello as chief commercialization officer. Watson was previously CEO at Genturi, a genomics technology startup. He was also chief commercial officer at RainDance Technologies, which was acquired by Bio-Rad Laboratories. Prior to Raindance, he was the vice president of SOLiD sequencing product management at Life Technologies, now part of Thermo Fisher Scientific. He also previously led the capillary electrophoresis sequencing business for Applied Biosystems, which became part of Life Technologies.

Scarpello was promoted from vice president of sales and business development to CCO. He joined Empire Genomics in 2009, and previously held numerous senior management roles with Enzo Life Sciences.

Feb 12, 2019

Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, Cameron Turtle

Caribou Biosciences has appointed Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, and Cameron Turtle to its scientific advisory board. 

Balskus is a professor of chemistry and chemical biology at Harvard University and an associate member of the Broad Institute of Harvard and MIT. Bhatt is an assistant professor of medicine (hematology) and genetics at Stanford University. Lee is a professor of pediatrics at Nationwide Children's Hospital and Ohio State University, and is also the founding director of the joint cellular therapy and cancer immunotherapy program between the Research Institute at Nationwide Children's Hospital and Ohio State University Comprehensive Cancer Center. Rathmell serves as director of the Vanderbilt Center for Immunobiology and as associate director of the Institute of Infection, Immunology and Inflammation at the Vanderbilt University Medical Center. Raje is a professor of Medicine at Harvard Medical School, director of the Center for Multiple Myeloma, and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. And Turtle is an associate member at Fred Hutchinson Cancer Research Center and an associate professor at the University of Washington.

The new members will join current scientific advisory board members and Caribou cofounders Jennifer Doudna and Martin Jinek.

Feb 08, 2019

David Anstey

Genomenon has appointed David Anstey as VP of sales and business department. Anstey previously served as VP of sales at Fabric Genomics. Prior to working at Fabric, Anstey held positions at Illumina, YarcData, and IDBS. 

Feb 08, 2019

Siddhartha Mukherjee

SEngine Precision Medicine has appointed Siddhartha Mukherjee to its advisory Board. Mukherjee is the Pulitzer Prize-winning author of the "The Emperor of All Maladies: A Biography of Cancer." Mukherjee is also an assistant professor of medicine and leading cancer researcher at Columbia University.

Feb 08, 2019

Martin Kunz

Twist Bioscience has appointed Martin Kunz as its senior VP of operations. Prior to Twist, he served as president of Eurofins Genomics US. Before serving as president, Kunz acted as chief technology officer at the firm. Prior to Eurofins, he served as chief information officer of Operon Biotechnologies. Kunz has also held a variety of positions at various companies in Switzerland. 

Feb 06, 2019

Susan Siegel

Illumina has named Susan Siegel to its board of directors. Siegel is chief innovation officer at General Electric and CEO of GE Ventures, which invests in startups and commercializes GE's intellectual property. Prior to joining GE, she was a general partner at Mohr Davidow Ventures, where she led investments in personalized medicine, digital health, and life sciences. Siegel was a founding representative member of the National Institutes of Health's National Center for Advancing Translational Sciences and also served on the Precision Medicine Initiative Working Group of the Advisory Committee to the NIH Director.

Feb 05, 2019

Gary Gregory

Perthera has appointed Gary Gregory as the firm's CEO, President, and board member. Gregory's 30 year experience spans several companies and positions, including executive officer roles across firms including Johnson & Johnson, Baxter, Kendal Healthcare, Neuronix, Advanced Dx, NeuroMetrix, and PrimeSource Healthcare. 

Jan 29, 2019

Jonathan Symonds, Sir John Chisholm, John Mattick, Mark Caulfield

Jonathan Symonds has been appointed as chair of Genomics England, replacing Sir John Chisholm, who stepped down this week. Symonds had been a senior non-executive director of the company since 2014.

In addition, John Mattick stepped down as CEO of Genomics England. He is temporarily replaced by Mark Caulfield, the company's chief scientist, who will serve as interim chief executive while a search for a permanent new CEO is ongoing.

Jan 25, 2019

John Steuart, Gail Marcus

John Steuart has resigned from Natera's board of directors. The board has also appointed Gail Marcus as chair of the audit committee. She joined Natera's board in March 2017 and currently serves as chair of the nominating and corporate governance committee.

Jan 25, 2019

Soren Germer, Michael Zody, Ana Bastiani-Posner

Soren Germer has been promoted to senior VP of genome technologies of the New York Genome Center. He previously served as the center's senior scientific director of sequencing operations, and before that, sequencing program manager. In his new role, Germer will lead the activities of the NYGC's sequencing and analysis teams.

Also, Michael Zody has been promoted to scientific director of computational biology of the NYGC, a new role. Zody will continue to provide scientific leadership to the computational biology team as well as lead new grants, foster partnerships, and serve as strategic scientific advisor.

In addition, Ana Bastiani-Posner has joined the NYGC as senior VP of finance and administration. Previously, she held executive finance roles at Allergan, Novartis Pharmaceuticals, and Schering-Plough.

Jan 24, 2019

Greg Thompson

GeneCapture has appointed Greg Thompson as its chief operating officer. Thompson will oversee the product design, commercialization, and medical device approvals for the firm's portable and rapid diagnostic for the point-of-care market. Thompson previously served as VP of design in the medical division and VP of global product design and development at Sanmina. Thompson earned a BSEE degree in computer engineering from North Dakota State University.

Jan 22, 2019

Michael Rasche

Metabolon has appointed Michael Rasche as its president of international business. Rasche will lead the firm's international business activities with a focus on customer and team expansion. Prior to Metabolon, Rasche acted as chief commercial officer at Definiens. Before Definiens, Rasche served as corporate VP of global commercial operations at Ayoxxa. He has also held leadership positions at Dako (now Agilent), Roche, and Bayer Diagnostics in Europe, as well as North and South America.

Jan 18, 2019

TJ Johnson, John Lubniewski

HTG Molecular Diagnostics has announced that TJ Johnson, the firm's current CEO, will assume the role of executive chairman of its board of directors. John Lubniewski, HTG's president and chief operating officer, will succeed Johnson as CEO. In addition, Ann Hanham will assume the role of lead independent director at the end of Q1 2019.

Lubniewski has served as HTG's president and COO since April 2018, joining the firm in 2011 as chief business officer. Before HTG, Lubniewski served in several leadership roles at Ventana, including senior VP and life cycle leader for platforms and clinical assays, as well as head of global marketing. Prior to Ventana, Lubniewski worked at Corning for over a decade in a variety of roles.

Jan 17, 2019

Deanna Church

Deanna Church has joined gene editing technology company Inscripta as senior director of mammalian applications. Previously, she was senior director of applications at 10x Genomics, and before that, senior director of genomics and content at Personalis. Prior to that, she was a staff scientist at the National Center for Biotechnology Information. Church holds a PhD in genomics, genetics, and molecular biology from the University of California, Irvine, and a BA in liberal arts from the University of Virginia.

Jan 14, 2019

Jonathan Jaglom, Gil Ronen

NRGene said this week that it has appointed Jonathan Jaglom as the firm's CEO. Jaglom succeeds NRGene's cofounder Gil Ronen, who has transitioned to the firm's president. Jaglom previously served as NRGene's chief operating officer. Prior to joining NRGene in 2018, Jaglom served as CEO of MakerBot. He has also held executive roles at Stratasys, including general manager and VP of sales operations. 

Jan 09, 2019

William Finger

Cancer Genetics has appointed William Finger as its executive VP of precision medicine and biopharma solutions. He will be responsible for developing and overseeing the company's precision medicine and biopharma and clinical trial business unit. Finger has more than 25 years of experience in the life sciences, diagnostics, and lab service industries. Before joining Cancer Genetics, he acted as managing director of precision medicine and diagnostics for Kineticos, a life science consultancy firm. Before Kineticos, Finger spent 12 years at Laboratory Corporation of America, where he held leadership positions in scientific affairs, preclinical services, biorepository, and operations.

Jan 08, 2019

Richard Compton

Richard Compton resigned as director of Metrichor, a sister company of Oxford Nanopore Technologies, last month. He was appointed to the firm's board in 2016 and was also general manager at Metrichor. Compton remains VP of commercial operations at Oxford Nanopore. He previously served as VP and general manager of the EMEA region at Illumina.

Jan 08, 2019

Ian Heynen

Ian Heynen has been named general manager of Sysmex Canada, a wholly owned subsidiary of Sysmex America. He will execute the firm's business strategy in the Canadian market and will report to Sysmex Canada CEO Andy Hay. Heynen was most recetly senior vice president of sales and marketing for Profound Medical. Prior to that he was acting president of the international division of Hologic. 

Jan 07, 2019

Samar Parikh

Binx Health has appointed Samar Parikh to its board of directors. Parikh has held various leadership positions at Amazon including global leader business development and strategy, and general manager CPG, consumer healthcare, and consumer healthcare innovation. Boston-based Binx is developing a desktop point-of-care platform called Io to perform rapid PCR-based detection in 30 minutes and with laboratory quality results. A multicenter, clinical study is currently underway to evaluate Io for clearance from the US Food and Drug Administration for chlamydia and gonorrhea. 

Jan 07, 2019

Cara Williams

Cara Williams has joined the scientific advisory board of data science company Genialis. She is vice president and head of immunology and respiratory disease research Germany at Boehringer Ingelheim. Prior to that, she was senior director of inflammation and remodeling research at Pfizer. Williams holds a PhD from Liverpool University.

Jan 07, 2019

Cindy Perettie

Foundation Medicine, a Roche company, has appointed Cindy Perettie as its CEO effective Feb. 4, replacing Troy Cox. Most recently, Perettie served as senior VP in global oncology product strategy at Roche's oncology unit. Prior to Roche, she acted as president of global development innovations at the Sarah Cannon Research Institute. Perettie has also held a number of positions at Genentech, also a unit of Roche, including VP of global regulatory operations and regional head of Europe, Middle East, and Africa operations and global development.

Jan 07, 2019

Jon Cohen, Geoff Monk

Jon Cohen has been appointed as executive chairman of BioReference Laboratories, a unit of Opko Health.

Most recently, he was senior vice president and group executive for diagnostic solutions at Quest Diagnostics. Prior to that, he was a managing director for health industries services at PricewaterhouseCoopers, and before that, chief medical officer at North Shore-Long Island Jewish Health System. Cohen holds a BS degree from the University of Miami and an MD degree from the University of Miami School of Medicine.

OpkoHealth has also promoted Geoff Monk to president of BioReference Laboratories. He joined the company last year as general manager.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.